Conferences - Results from #180

ASCO GU 2021: Phase IIB Trial of Oral ModraDoc006/r as a Tolerable and Effective Option in Comparison with Intravenous Docetaxel in Metastatic Castration-Resistant Prostate Cancer February 13, 2021

ASCO GU 2021: Randomized Phase II Trial of Radium-223 Plus Enzalutamide vs Enzalutamide Alone in Metastatic Castration-Refractory Prostate Cancer: Final Efficacy and Safety Results February 13, 2021

ASCO GU 2021: Progress and Promise in Treatment Personalization for Advanced Prostate Cancer Panel Discussion February 13, 2021

ASCO GU 2021: Imaging Modality And Frequency In Surveillance of Stage I Seminoma Testicular Cancer: Results From A Randomized, Phase III, Factorial Trial (TRISST) February 13, 2021

ASCO GU 2021: SEMS trial: Result of a Prospective, Multi-Institutional Phase II Clinical Trial of Surgery In Early Metastatic Seminoma February 13, 2021

ASCO GU 2021: EV-201 Cohort 2: Enfortumab Vedotin In Cisplatin-Ineligible Patients with Locally Advanced or Metastatic Urothelial Cancer Who Received Prior PD-1/PD-L1 Inhibitors February 13, 2021

ASCO GU 2021: Optimal Therapy for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer in the Non-cystectomy Candidate - Systemic February 13, 2021

ASCO GU 2021: Safety and Efficacy Of Perioperative Cisplatin/Gemcitabine And Durvalumab For Operable Muscle-Invasive Urothelial Carcinoma: SAKK 06/17 February 13, 2021

ASCO GU 2021: Primary Results of EV-301: A Phase III Trial of Enfortumab Vedotin Versus Chemotherapy in Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma February 13, 2021

ASCO GU 2021: Atezolizumab Monotherapy vs Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Outcomes by PD-L1 Status In Cisplatin-Ineligible Patients From the Phase III IMvigor130 Study February 12, 2021

ASCO GU 2021: Beyond the Basics: Harnessing the Immune System to Fight Prostate Cancer February 12, 2021

ASCO GU 2021: Optimal Therapy for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer in the Non-cystectomy Candidate - Intravesical February 12, 2021

ASCO GU 2021: The von Hippel-Lindau Tumor Suppressor Protein: Rosetta Stone for Kidney Cancer Pathogenesis and Treatment February 12, 2021

ASCO GU 2021: Clinically Significant Events Associated with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treatments February 12, 2021

ASCO GU 2021: Clinical Conundrums of Genomically Driven Prostate Cancer - Case Panel Discussion February 12, 2021

ASCO GU 2021: Phase IIb Trial of Oral ModraDoc006/ritonavir as a Tolerable and Effective Option in Comparison with Intravenous Docetaxel in mCRPC February 12, 2021

ASCO GU 2021: Beyond the Basics: Harnessing the Immune System to Fight Prostate Cancer February 12, 2021

ASCO GU 2021: Back to Basics in Personalization: Returning to PTEN February 12, 2021

ASCO GU 2021: Association of Co-Occurring Gene Alterations and Clinical Activity of Rucaparib in Patients with BRCA1 or BRCA2 Mutated (BRCA+) Metastatic Castration-Resistant Prostate Cancer (mCRPC) February 12, 2021

ASCO GU 2021: Approaches to Immune Checkpoint Inhibitor Maintenance Therapy in Metastatic Urothelial Cancer: A Qualitative Analysis of Oncology Providers in the United States February 12, 2021

Page 10 of 392